-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
IR415
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/452967-14-5.gif)
| Category | Hepatitis B Virus (HBV) |
| CAS | 452967-14-5 |
| Description | IR415 is an effective anti-HBV drug that inhibits HBV replication by blocking hepatitis B virus X protein (HBx) activity. IR415 selectively interacts with HBx (Kd = 2 nM), blocks HBV-mediated RNAi inhibition and reverses the inhibitory effect of HBx protein on dicer endoribonuclease activity. |
Product Information
| Synonyms | 1-[3-(1-Imidazolyl)propyl]-3-(2,4-difluorophenyl)thiourea; N-(2,4-difluorophenyl)-N'-[3-(1H-imidazol-1-yl)propyl]thiourea; 1-(2,4-Difluorophenyl)-3-[3-(1H-imidazol-1-yl)propyl]thiourea |
| IUPAC Name | 1-(2,4-difluorophenyl)-3-(3-imidazol-1-ylpropyl)thiourea |
| Molecular Weight | 296.34 |
| Molecular Formula | C13H14F2N4S |
| Canonical SMILES | C1=CC(=C(C=C1F)F)NC(=S)NCCCN2C=CN=C2 |
| InChI | InChI=1S/C13H14F2N4S/c14-10-2-3-12(11(15)8-10)18-13(20)17-4-1-6-19-7-5-16-9-19/h2-3,5,7-9H,1,4,6H2,(H2,17,18,20) |
| InChIKey | KRSBPLFMLHNMPU-UHFFFAOYSA-N |
| Boiling Point | 439.6±55.0°C at 760 mmHg |
| Purity | ≥98% |
| Density | 1.3±0.1 g/cm3 |
| Solubility | Soluble in DMSO |
| Appearance | White to Beige Powder |
| Storage | Store at 2-8°C |
| Complexity | 319 |
| Exact Mass | 296.09072396 |
| Target | HBV |
| XLogP3-AA | 1.8 |
